Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 6
Encontrada(s) 1 página(s)

Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

Disappearance of recurrent pancreatitis after splenectomy in familial chylomicronemia syndrome

  • Marco-Benedí, V.
  • Lamiquiz-Moneo, I.
  • Álvarez-Sala, L.A.
  • Civeira, F.
Background and aims: Recurrent pancreatitis is a severe complication of familial chylomicronemia syndrome (FCS) mainly secondary to lipoprotein lipase deficiency. The mechanism and interindividual variability of pancreatitis in FCS are not fully understood, but abnormalities in the drainage system of pancreatic veins could be involved. Methods and results: Two cases of typical FCS are described with a past history of recurrent pancreatitis that dramatically improved after splenectomy performed in both cases for reasons non-related to FCS. Conclusions: These are the first reports of the disappearance of pancreatitis after splenectomy in FCS and they should be considered of anecdotal nature at this time. The disappearance of pancreatitis following splenectomy could be in part due to subsequent improvements in pancreatic drainage. Extrahepatic portal hypertension induced by hypertriglyceridemic splenomegaly leading to pancreatic congestion could also be a contributing factor.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

Comparative efficacy between atorvastatin and rosuvastatin in the prevention of cardiovascular disease recurrence

  • Perez-Calahorra, S.
  • Laclaustra, M.
  • Marco-Benedi, V.
  • Pinto, X.
  • Sanchez-Hernandez, R.M.
  • Plana, N.
  • Ortega, E.
  • Fuentes, F.
  • Civeira, F.
Background: There is no randomized clinical trials with recurrence of atherosclerotic cardiovascular disease (ASCVD) as a major outcome with rosuvastatin. In order to analyze potential differences in the clinical response to atorvastatin and rosuvastatin in secondary ASCVD prevention, we have analyzed the clinical evolution of those subjects of the Dyslipemia Registry of the Spanish Society of Arteriosclerosis (SEA) who at the time of inclusion in the Registry had already suffered an ASCVD. Methods: This observational, retrospective, multicenter, national study was designed to determine potential differences between the use of atorvastatin and rosuvastatin in the ASCVD recurrence. Three different follow-up start-times were performed: time of inclusion in the registry; time of first event if this occurred after 2005, and time of first event without date restriction. Results: Baseline characteristics were similar between treatment groups. Among atorvastatin or rosuvastatin users, 89 recurrences of ASCVD were recorded (21.9%), of which 85.4% were coronary. At the inclusion of the subject in the registry, 345 participants had not suffered a recurrence yet. These 345 subjects accumulated 1050 person-years in a mean follow-up of 3 years. Event rates were 2.73 (95% CI: 1.63, 4.25) cases/100 person-years and 2.34 (95% CI: 1.17, 4.10) cases/100 person-years in the atorvastatin and rosuvastatin groups, respectively. There were no statistically significant differences between the two groups independently of the follow-up start-time. Conclusions: This study does not find differences between high doses of rosuvastatin and atorvastatin in the recurrence of ASCVD, and supports their use as clinically equivalent in secondary prevention of ASCVD.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

Behavioural cardiovascular risk factors and prevalence of diabetes in subjects with familial hypercholesterolaemia

  • Perez-Calahorra, S.
  • Civeira, F.
  • Guallar-Castillón, P.
  • Pinto, X.
  • Banegas, J. R.
  • Pedro-Botet, J.
  • Suarez-Tembra, M.
  • Mauri, M.
  • Soler, C.
  • Rodriguez-Artalejo, F.
  • Laclaustra, M.
A low prevalence of type 2 diabetes mellitus has been reported in familial hypercholesterolaemia. Whether a healthier lifestyle could explain it has not been explored. This cross-sectional study determines the prevalence of lifestyle-related cardiovascular risk factors in heterozygous familial hypercholesterolaemia (HeFH) from the Dyslipidaemia Registry of the Spanish Atherosclerosis Society and in the ENRICA study, a representative sample of the adult Spanish general population, weighted to match the age and sex distribution of the HeFH sample. A total of 2185 HeFH patients and 11, 856 individuals from ENRICA were included. HeFH had lower body mass index and fewer of them were smokers than in the reference population. A model adjusted for age, sex and body mass index showed that HeFH more frequently had cardiovascular disease (odds ratio (OR) 23.98; 95% confidence interval (CI) 18.40–31.23) and hypertension (OR 1.20; 95% CI 1.07–1.35), and took anti-hypertensive medication (OR 1.36; 95% CI 1.18–1.56) and anti-diabetic medication (OR 1.25; 95% CI 1.00–1.56), but less frequently were smokers (OR 0.79; 95% CI 0.71–0.89). In a HeFH subsample (n = 513) with complete blood glucose information, those patients without cardiovascular disease showed lower prevalence of smoking and type 2 diabetes mellitus, lower body mass index and glucose, and higher diastolic blood pressure than the Spanish population. The differences in type 2 diabetes mellitus were justified mostly by the difference in body mass index. Body mass index adjustment also showed higher prevalence of hypertension and use of anti-hypertensive drugs in HeFH. In summary, HeFH patients had lower body mass index, which may contribute to explaining the lower prevalence of diabetes, and lower current smoking but higher hypertension. © The European Society of Cardiology 2020.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

Disbetalipoproteinemia y otras alteraciones relacionadas con la apolipoproteína E

  • Cenarro, A.
  • Bea, A.M.
  • Gracia-Rubio, I.
  • Civeira, F.
La disbetalipoproteinemia o hiperlipoproteinemia tipo III es una hiperlipemia mixta grave consecuencia de la acumulación de partículas remanentes de quilomicrones y VLDL en plasma, también llamadas β-VLDL. Se produce por un defecto en el reconocimiento por parte de los receptores hepáticos LDL y LRP de las β-VLDL. Mutaciones en el gen de APOE, especialmente los sujetos homocigotos para el alelo ɛ2/ɛ2, son las responsables de esta falta de reconocimiento por los receptores. La disbetalipoproteinemia representa el 2-5% de las dislipemias mixtas atendidas en las unidades de lípidos; es altamente aterogénica y predispone a una ateromatosis difusa, tanto coronaria, vascular periférica y carotídea, por lo que es necesario un diagnóstico y tratamiento precoz. La presencia de hipertrigliceridemia, con cocientes colesterol no-HDL/apolipoproteína B > 1,43 (en mg/dL), seguido de genotipado de APOE es el método de elección en el diagnóstico de la disbetalipoproteinemia. Es una dislipemia que responde bien al tratamiento higiénico-dietético, aunque muchas veces la combinación estatina y fenofibrato es necesaria para lograr un control óptimo. Dysbetalipoproteinaemia (or type III hyperlipoproteinaemia) is a severe mixed hyperlipidaemia resulting from the accumulation of remnant chylomicron and VLDL particles in plasma, also called β-VLDL. It is caused by a defect in the recognition by hepatic LDL and lipoprotein receptor-related protein (LRP) of β-VLDL. Mutations in the APOE gene, especially in subjects homozygous for the ɛ2/ɛ2 allele, are responsible for this lack of receptor recognition. Dysbetalipoproteinaemia represents 2-5% of the mixed dyslipidaemias seen in Lipid Units, is highly atherogenic and predisposes to diffuse atheromatosis, either coronary, peripheral vascular, or carotid, so early diagnosis and treatment is necessary. The presence of hypertriglyceridaemia, with non-HDL cholesterol/apolipoprotein B ratios > 1.43 (in mg/dL) followed by APOE genotyping is the method of choice in the diagnosis of dysbetalipoproteinaemia. It is a dyslipidaemia that responds well to hygienic-dietary treatment, although the combination of statin and fenofibrate is often necessary to achieve optimal control.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

Novel protocol for the transcriptomic analysis of endothelial extracellular vesicles in atherosclerosis

  • Saenz-Pipaon, Goren
  • Cenarro, Ana
  • Zazpe, Jon
  • Goñi-Oloriz, Miriam
  • Martinez-Aguilar, Esther
  • Machado, Florencio J.D.
  • Marchese, Francesco P.
  • Orbe, Josune
  • López-Andrés, Natalia
  • Civeira, Fernando
  • Paramo, Jose A.
  • Lara-Astiaso, David
  • Roncal, Carmen
Introduction: Despite the key role of the endothelium in atherosclerosis, there are no direct techniques for its analysis. The study of extracellular vesicles of endothelial origin (EEVs), might lead to the identification of molecular signatures and early biomarkers of atherosclerosis. The aim of this work was to set up the methods for EEVs separation and transcriptomic analysis. Methods: We adapted an antibody-magnetic-bead based immunocapture protocol for plasma EEVs separation from control (G1), subclinical atherosclerosis (G2) and peripheral artery disease subjects (PAD) (G3), and modified an ultra-low input RNASeq method (n = 5/group). By bioinformatics analysis we compared the transcriptome of plasma EEVs with that of human aortic endothelial cells (TeloHAECs), and then, searched for differentially expressed genes (DEG) among EEVs of G1, G2 and G3. From those DEG, UCP2 was selected for further validation in plasma EVs (qPCR), and in vitro, in stimulated TeloHAECs (IL-1β, TNFα, oxLDL and hypoxia). Results: The RNASeq analysis of plasma EEVs rendered 1667 genes enriched in transcripts expressed by TeloHAECs (NES: 1.93, p adjust = 1.4e−73). One hundred seventy DEGs were identified between G2 vs G1, and 180 between G3 vs G1, of which 17 were similarly expressed in G2 and G3 vs control, including UCP2. IL-1β and TNFα (10 ng/mL, p < 0.05), hypoxia (1% O2, p = 0.05) and oxLDL (100 μg/mL, p = 0.055) reduced UCP2 expression in TeloHAECs. Conclusions: We set up a protocol for EEVs separation and sequencing that might be useful for the identification of early markers of endothelial dysfunction in atherosclerosis. Introducción: A pesar del papel clave del endotelio en la aterosclerosis, no existen técnicas directas para su análisis. El estudio de las vesículas extracelulares de origen endotelial (EEV) podría facilitar la identificación de firmas moleculares y biomarcadores tempranos de aterosclerosis. El objetivo de este trabajo fue establecer los métodos para la separación de EEV y su análisis transcriptómico. Métodos: Adaptamos un protocolo de inmunocaptura con anticuerpos y microesferas magnéticas para la separación de las EEV del plasma de sujetos control (G1), con aterosclerosis subclínica (G2) y con enfermedad arterial periférica (G3), y modificamos un método de RNASeq para su análisis transcriptómico (n = 5/grupo). Comparamos el transcriptoma de las EEV plasmáticas con el de células endoteliales de aorta humana (TeloHAEC) e identificamos genes diferencialmente expresados (DEG) entre los grupos de pacientes, incluyendo UCP2, validado en EV plasmáticas (qPCR) e in vitro, en TeloHAECs tratadas con IL-1β, TNF-α, oxLDL e hipoxia. Resultados: El RNASeq de las EEV plasmáticas detectó 1.667 genes enriquecidos en transcritos expresados por las TeloHAECs (NES: 1,93, ajuste p = 1,4e−73). Se identificaron 170 DEG entre los grupos G2 vs. G1 y 180 entre G3 vs. G1, de los cuales 17 se expresaron de forma similar en G2 y G3 vs. control, incluyendo UCP2. El tratamiento con IL-1β y TNF-α (10 ng/ml, p < 0,05), hipoxia (1% O2, p = 0,05) y oxLDL (100 μg/ml, p = 0,055) redujo la expresión de UCP2 en las TeloHAEC. Conclusiones: Hemos puesto a punto un protocolo para la separación y la secuenciación de EEV que podría ser útil para la identificación de marcadores tempranos de disfunción endotelial en aterosclerosis.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

Non-genetic and genetic determinants of serum selenium and selenium species in the Aragon Workers Health Study

  • Rodriguez-Hernandez, Zulema
  • Paredes-Douton, Anabel
  • Galvez-Fernandez, Marta
  • Grau-Perez, Maria
  • Sotos-Prieto, Mercedes
  • Rentero-Garrido, Pilar
  • Gonzalez-Estecha, Montserrat
  • Llorente-Ballesteros, Maria Teresa
  • Gomez-Ariza, Jose L.
  • Callejon-Leblic, Belen
  • Fernandez-Navarro, Pablo
  • Laclaustra, Martin
  • Cenarro, Ana
  • Civeira, Fernando
  • Glabonjat, Ronald A.
  • Monleon, Daniel
  • Pastor-Barriuso, Roberto
  • Moreno-Franco, Belen
  • Garcia-Barrera, Tamara
  • Tellez-Plaza, Maria
Understanding potential determinants of selenium biomarkers can help to unravel selenium health effects. We evaluated the contribution of non-genetic (sociodemographic and lifestyle) and genetic factors to serum selenium biomarkers and selenium species (quantified as selenium) including selenium in glutathione peroxidase (GPx), selenoprotein P (SeP), selenoalbumin (SeAlb) and total selenometabolites (Se-metabolites) in the Aragon Workers Health Study (AWHS), a predominantly male cohort of car assembly factory workers in Spain. Total serum selenium and selenium species were measured by HPLC/ICP-QQQ-MS in 1624 AWHS participants. Blood and urine selenium, measured by ICP-MS, were available in a subset. A Healthy Lifestyle Score (HLS) included Mediterranean diet, physical activity, smoking, BMI and alcohol intake. Candidate gene and genome-wide discovery analyses (CGA and GDA, respectively) were based on TOPMed imputed SNPs. In sex and age-adjusted models, overall HLS, physical activity, and specific foods intake showed positive associations with serum total selenium, SeAlb and Se-metabolites concentrations. The associations between smoking status and BMI with total serum selenium; age, smoking status, BMI and meat intake with SeAlb; and smoking status with Se-metabolites, were inverse. In the GDA, we identified 20, 24, 21, 26, 16, 20 and 68 independent genetic loci for serum total selenium, GPx, SeP, SeAlb, Se-metabolites, and total blood and urine selenium, respectively, with some overlapping genes also relevant in the CGA. Enrichment analysis pointed to biological pathways including circadian rhythm regulation, immune system processes, signaling and receptor- and transporter-related pathways. The explained variability of selenium markers ranged from 15 % for SeP to 21 % for SeAlb and from 0.2 % for SeP to 3.5 % for SeAlb in environmental determinants-adjusted models with and without the specific selenium biomarker polygenic score, respectively. While the genetic contribution is substantial, selenium status might be influenced by reinforced healthy lifestyle interventions. Follow-up genetic studies to evaluate selenium health consequences are granted.